• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Technology·EXPLEOSOL.NS
Share

Expleo Solutions Limited Stocks

₹ 824.65Last Updated 20.07.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 127.18M

₹ 824.65
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Expleo Solutions Limited, encompassing its various subsidiaries, specializes in providing global software validation and verification services, primarily catering to the banking, financial services, and insurance industries. The company's comprehensive suite of services includes quality engineering, quality management, robust software testing, DevOps implementation, and test automation. Established in 1998 and headquartered in Chennai, India, the firm operated under the name SQS India BFSI Limited until its rebranding to Expleo Solutions Limited in April 2019. Expleo Solutions Limited is a subsidiary of Expleo Technology Germany GmbH.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of EXPLEOSOL.NS is 1353 and suggests 70.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 04:00

SpaceX lost more than $1 trillion in market value in a month

21.07.2026 03:16

From hockey sticks to cement: The U.S. imposes 50 percent tariffs on imports from Canada

21.07.2026 01:55

Box office receipts from Nolan's "Odyssey" boosted theater stocks

21.07.2026 01:21

"Reality Check": Tensions with Iran Have Halted the Rally in U.S. Stocks

21.07.2026 00:16

Brent Crude Approaches $90: Trump Says Iran Will "Pay" for the Killing of U.S. Military Personnel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026